Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label pilot study of subcutaneous SOM230 in rare duodeno-pancreatic neuroendocrine tumors and selected pituitary tumors
2006-002877-30Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2007
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR in Gastroenteropancreatic Carcinoid Tumor, insulinoma, glucagonoma and 7 more, sponsored by Novartis. Primary endpoints: Biochemical tumor marker response at 3 and 6 months, Tumor response at 3 and 6 months and 5 more. Started Jun 2007; status: terminated.
02
Drugs
pasireotide LAR
03
Conditions
Gastroenteropancreatic Carcinoid TumorinsulinomaglucagonomaPancreatic VIPoma (VIPoma)gastrinoma
Beyond the preview
Go deeper on 2006-002877-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002877-30.